Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.40 |
| ▸ | MEN1 | O00255 | 7/20 | 0.40 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1309430 | 0.87 | GAA (0.38) | MAPTLMNAPOLBPKMKMT2A | |
| SCHEMBL6134918 | 0.77 | CES2 (0.33) | — | |
| SCHEMBL7443750 | 0.75 | CYP4F2 (0.45) | MAPTLMNAPOLBPKMKMT2A | |
| SCHEMBL27987602 | 0.74 | LMNA (0.38) | MAPTLMNAPOLBPKMKMT2A | |
| SCHEMBL8071102 | 0.74 | CYP4F2 (0.45) | MAPTLMNAPOLBPKMKMT2A | |
| SCHEMBL11345271 | 0.74 | CYP4F2 (0.49) | MAPTLMNAPOLBPKMKMT2A | |
| Trifluoroacetic Acid SCHEMBL6182271 | 0.74 | OPRM1 (0.43) | MAPTLMNAPOLBPKMKMT2A | |
| SCHEMBL7557203 | 0.73 | CYP3A4 (0.44) | MAPTLMNAPOLBKMT2AMEN1 | |
| SCHEMBL1308813 | 0.73 | CYP3A4 (0.44) | MAPTLMNAPOLBKMT2AMEN1 | |
| SCHEMBL21399965 | 0.73 | CYP4F2 (0.47) | MAPTLMNAPOLBPKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1187614-A4 | SUBSTITUTED PIPERIDINES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20020137664-A1 | Substituted piperidines as melanocortin-4 receptor agonists | MERCK & CO., INC. | 2002-09-26 | — | — | US | disclosed |
| EP-1187614-A1 | SUBSTITUTED PIPERIDINES AS MELANOCORTIN-4 RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2002-03-20 | — | — | EP | disclosed |
| US-6350760-B1 | OBESITY, DIABETES, SEXUAL DYSFUNCTION; | MERCK & CO., INC. | 2002-02-26 | — | — | US | disclosed |
| WO-2000074679-A1 | SUBSTITUTED PIPERIDINES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137664-A1 | Substituted piperidines as melanocortin-4 receptor agonists | MC4R, MC5R, MC3R | MAPT 3276/4885LMNA 4606/4885POLB 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.